Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Fig. 2

Pathological and genetic profiles, during in vivo passages, of xenograft derived from the patient’s cancer. A Morphological and immunohistochemical staining results during passaging of patient derived xenografts (PDX). Tumors excised from mice with engrafted patient tumors were defined as the first generation (G1), and the generations of tumors excised at passaging were defined in order as G2, G3, and G4. HE, Hematoxylin Eosin stain; HER2, human epidermal growth factor receptor 2; CK7, Cytokeratin 7; CK20, Cytokeratin 20; GATA3, GATA binding protein 3. B HER2 copy number and ratio of HER2 E401G to wild type by droplet digital PCR. The left figure shows the result of HER2 copy number assay; the right figure shows the result of mutation detection assay to check the mutant-to-wild-type ratio

Back to article page